The optimal duration of immune checkpoint blockade (ICB) in lung cancer remains undefined. Indefinite treatment in long-term responders increases healthcare burden, exposes patients to avoidable toxicities, and is not supported by any clinical and biological rationale or translational data. Prospective strategies to determine the optimal duration of immunotherapy in lung cancer are urgently needed.
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)
Annals of Oncology | | N. Frost, M. Joosten, J. Franzen, M. Wiesweg, A. Rasokat, J. Kulhavy, J. Kollmeier, N. Reinmuth, C. Grohé, J. Roeper, A. Rittmeyer, S. Heinzen, M. Wermke, C. Wesseler, P. Christopoulos, D. Kauffmann-Guerrero, A. Althoff, A. Bleckmann, M. Collienne, E. Berezucki, T. Overbeck, C. Kropf-Sanchen, F. Griesinger, M. Sebastian, M. Schuler, S. Braun, C. Wenzel, C. Furth, J. Wolf, P. Bischoff, M. Reck, National Network Genomic Medicine Lung Cancer Germany
Topics: lung-cancer, cervical-cancer, immunotherapy, research